ERBB2 and breast carcinoma: Our novel finding that these proteins are co-expressed in breast tumor epithelial cells and the observation that enavatuzumab and trastuzumab synergize in inhibiting the growth of HER2-positive breast cancer cells in vitro suggests a functional interaction between these two proteins.